机械取栓成功再灌注后动脉内阿替普酶治疗急性卒中:PEARL随机临床试验
PEARL多中心随机临床试验在中国28家医院纳入324例前循环大血管闭塞、发病24小时内且取栓后成功再灌注(eTICI≥2b50)的急性缺血性卒中患者,随机接受动脉内阿替普酶0.225 mg/kg(最大20 mg)或标准治疗。主要终点90天mRS 0-1分比例动脉内阿替普酶组44.8%(73/163) vs 标准治疗组30.2%(48/159),校正RR 1.45(95%CI 1.08-1.96),P=.01。症状性颅内出血36小时内两组4.3% vs 5.0%(校正RR 0.85,95%CI 0.43-1.69),无显著差异;全因死亡90天17.1% vs 11.3%(校正HR 1.60,95%CI 0.88-2.89),任何颅内出血36小时内32.9% vs 26.9%(校正RR 1.22,95%CI 0.92-1.63),均未达统计学显著。
要点
- 纳入标准:前循环大血管闭塞、发病24小时内、取栓后eTICI≥2b50成功再灌注,允许指南推荐的静脉溶栓。
- 动脉内阿替普酶剂量0.225 mg/kg,最大20 mg,取栓成功后经动脉给药。
- 90天mRS 0-1分:动脉内阿替普酶组44.8%(73/163) vs 标准治疗组30.2%(48/159),校正RR 1.45(95%CI 1.08-1.96),P=.01。
- 症状性颅内出血36小时内:4.3%(7/164) vs 5.0%(8/160),校正RR 0.85(95%CI 0.43-1.69),P=.67,无显著差异。
- 全因死亡90天17.1%(28/164) vs 11.3%(18/160),校正HR 1.60(95%CI 0.88-2.89),P=.12;任何颅内出血36小时内32.9%(54/164) vs 26.9%(43/160),校正RR 1.22(95%CI 0.92-1.63),P=.17,均未达统计学显著。
适用人群与场景
- 前循环大血管闭塞急性缺血性卒中患者,发病24小时内,取栓后达到成功再灌注(eTICI评分≥2b50)。
- 允许接受指南推荐的静脉溶栓治疗。
- 研究在中国28家医院进行,随机时间2023年8月1日至2024年10月16日,最终随访2025年1月7日。
诊断标准与关键阈值
- 成功再灌注定义为取栓后expanded Thrombolysis in Cerebral Infarction(eTICI)评分≥2b50。
- 主要终点为90天改良Rankin量表(mRS)评分0或1分(0分无症状,6分死亡;0或1分表示极佳结局)。
处置流程与药物剂量
- 取栓成功再灌注后,动脉内给予阿替普酶0.225 mg/kg,最大剂量20 mg(动脉内阿替普酶组n=164)。
- 标准治疗组(n=160)不接受动脉内阿替普酶。
红旗征与不能漏的情况
- 症状性颅内出血36小时内:动脉内阿替普酶组4.3%(7/164) vs 标准治疗组5.0%(8/160),校正RR 0.85(95%CI 0.43-1.69),P=.67。
- 任何颅内出血36小时内:动脉内阿替普酶组32.9%(54/164) vs 标准治疗组26.9%(43/160),校正RR 1.22(95%CI 0.92-1.63),P=.17。
- 全因死亡90天内:动脉内阿替普酶组17.1%(28/164) vs 标准治疗组11.3%(18/160),校正HR 1.60(95%CI 0.88-2.89),P=.12;原文结论指出动脉内阿替普酶组全因死亡和任何颅内出血发生率更高,但差异未达统计学显著。
研究设计与关键结果
- 多中心随机临床试验,纳入324例前循环大血管闭塞卒中患者(中位年龄68岁,IQR 58-75岁;女性99例,30.6%),随机分为动脉内阿替普酶组(n=164)和标准治疗组(n=160),每组1例失访。
- 主要终点90天mRS 0-1分:动脉内阿替普酶组44.8%(73/163) vs 标准治疗组30.2%(48/159),校正RR 1.45(95%CI 1.08-1.96),P=.01。
- 症状性颅内出血36小时内:动脉内阿替普酶组4.3%(7/164) vs 标准治疗组5.0%(8/160),校正RR 0.85(95%CI 0.43-1.69),P=.67。
- 全因死亡90天内:动脉内阿替普酶组17.1%(28/164) vs 标准治疗组11.3%(18/160),校正HR 1.60(95%CI 0.88-2.89),P=.12。
- 任何颅内出血36小时内:动脉内阿替普酶组32.9%(54/164) vs 标准治疗组26.9%(43/160),校正RR 1.22(95%CI 0.92-1.63),P=.17。
证据类型、等级与局限
- 证据类型:多中心随机临床试验(RCT)。
- 试验注册:ClinicalTrials.gov标识NCT05856851。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于前循环大血管闭塞、发病24小时内、取栓后达到eTICI≥2b50成功再灌注的急性缺血性卒中患者,动脉内阿替普酶0.225 mg/kg(最大20 mg)可使90天极佳功能结局(mRS 0-1)比例从30.2%提高至44.8%(校正RR 1.45,95%CI 1.08-1.96)。
- 动脉内阿替普酶组症状性颅内出血36小时内与标准治疗组无显著差异(4.3% vs 5.0%,校正RR 0.85,95%CI 0.43-1.69)。
- 动脉内阿替普酶组全因死亡90天17.1% vs 标准治疗组11.3%(校正HR 1.60,95%CI 0.88-2.89),任何颅内出血36小时内32.9% vs 26.9%(校正RR 1.22,95%CI 0.92-1.63),差异未达统计学显著,但原文结论指出动脉内阿替普酶组全因死亡和任何颅内出血发生率更高。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Functional outcomes in patients with acute ischemic stroke due to large-vessel occlusion who undergo thrombectomy remain suboptimal, and the benefits of intra-arterial alteplase after thrombectomy remain uncertain.
OBJECTIVE: To investigate whether treatment with intra-arterial alteplase after successful endovascular reperfusion improves functional outcomes among patients with acute, anterior-circulation, large-vessel occlusion stroke.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized clinical trial recruited patients with anterior-circulation, large-vessel occlusion stroke within 24 hours of symptom onset who achieved successful reperfusion (expanded Thrombolysis in Cerebral Infarction scale score of ≥2b50) after thrombectomy. Guideline-based intravenous thrombolysis was allowed. Patients were randomized between August 1, 2023, and October 16, 2024, and the trial was conducted at 28 hospitals in China. Final follow-up occurred on January 7, 2025.
INTERVENTIONS: Intra-arterial alteplase treatment (n = 164) with 0.225 mg/kg (maximum dose of 20 mg) vs standard treatment (n = 160).
MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients with a modified Rankin Scale score of 0 or 1 at 90 days (score range, 0 [no symptoms] to 6 [death]; a score of 0 or 1 indicates an excellent outcome). The safety outcomes included symptomatic intracranial hemorrhage within 36 hours of randomization, all-cause mortality within 90 days, and any intracranial hemorrhage within 36 hours.
RESULTS: Of the 324 patients randomized (median age, 68 years [IQR, 58-75 years]; 99 were female [30.6%]), 1 patient in each group was lost to follow-up. The proportion of patients with a modified Rankin Scale score of 0 or 1 at 90 days was 44.8% (73/163) in the intra-arterial alteplase group vs 30.2% (48/159) in the standard treatment group (adjusted risk ratio [RR], 1.45 [95% CI, 1.08-1.96]; P = .01). The proportion of patients with symptomatic intracranial hemorrhage within 36 hours was 4.3% (7/164) in the intra-arterial alteplase group vs 5.0% (8/160) in the standard treatment group (adjusted RR, 0.85 [95% CI, 0.43-1.69]; P = .67). The proportion of patients with all-cause mortality within 90 days was 17.1% (28/164) in the intra-arterial alteplase group vs 11.3% (18/160) in the standard treatment group (adjusted hazard ratio, 1.60 [95% CI, 0.88-2.89]; P = .12). The proportion of patients with any intracranial hemorrhage within 36 hours was 32.9% (54/164) in the intra-arterial alteplase group vs 26.9% (43/160) in the standard treatment group (adjusted RR, 1.22 [95% CI, 0.92-1.63]; P = .17).
CONCLUSIONS AND RELEVANCE: Among patients with acute, anterior-circulation, large-vessel occlusion stroke who achieved successful endovascular reperfusion by mechanical thrombectomy, intra-arterial alteplase resulted in a higher likelihood of excellent outcomes at 90 days. The incidence of all-cause mortality and any intracranial hemorrhage was higher in patients who received intra-arterial alteplase, although these differences were not statistically significant.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05856851.
参考来源
- Yang X, He X, Xu Y, et al. Intra-Arterial Alteplase After Successful Endovascular Reperfusion in Acute Stroke: The PEARL Randomized Clinical Trial. JAMA. 2025. PMID: 42262770. doi:10.1001/jama.2025.16876
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。